HRP20150952T1 - Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe - Google Patents
Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20150952T1 HRP20150952T1 HRP20150952TT HRP20150952T HRP20150952T1 HR P20150952 T1 HRP20150952 T1 HR P20150952T1 HR P20150952T T HRP20150952T T HR P20150952TT HR P20150952 T HRP20150952 T HR P20150952T HR P20150952 T1 HRP20150952 T1 HR P20150952T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- cancer
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Claims (9)
1. Najmanje jedan spoj naznačen time da je odabran od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i/ili najmanje jedna njihova farmaceutski prihvatljiva sol.
2. Najmanje jedan spoj prema zahtjevu 1 naznačen time da je odabran od:
[image]
[image]
[image]
i/ili najmanje jedna njihova farmaceutski prihvatljiva sol.
3. Spoj prema zahtjevu 1 naznačen time da je:
[image]
i/ili najmanje jedna njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 1 naznačen time da je:
[image]
5. Pripravak naznačen time da sadrži najmanje jedan spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, i/ili najmanje jednu njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljiv nosač.
6. Najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i/ili najmanje jedna njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje.
7. Najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i/ili najmanje jedna njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka.
8. Najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i/ili najmanje jedna njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka prema zahtjevu 7, pri čemu je rak odabran od raka pluća, raka glave i vrata, kolorektalnog raka, raka gušterače, raka debelog crijeva, raka dojke, raka jajnika, raka prostate, raka želuca, raka bubrega, raka jetre, raka mozga, raka kosti, te leukemije.
9. Najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i/ili a najmanje jedna njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka prema zahtjevu 7, pri čemu se spoj daje u kombinaciji s antineoplastičnim sredstvom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009076321 | 2009-12-31 | ||
| EP13198224.1A EP2719699B1 (en) | 2009-12-31 | 2010-12-30 | Certain triazolopyrazines, compositions thereof and methods of use therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150952T1 true HRP20150952T1 (hr) | 2015-10-09 |
Family
ID=44226181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221090TT HRP20221090T1 (hr) | 2009-12-31 | 2010-12-30 | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe |
| HRP20150952TT HRP20150952T1 (hr) | 2009-12-31 | 2015-09-08 | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe |
| HRP20202017TT HRP20202017T1 (hr) | 2009-12-31 | 2020-12-17 | Sintetski međuprodukt koristan u dobivanju triazolopiridina inhibitora c-met |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221090TT HRP20221090T1 (hr) | 2009-12-31 | 2010-12-30 | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202017TT HRP20202017T1 (hr) | 2009-12-31 | 2020-12-17 | Sintetski međuprodukt koristan u dobivanju triazolopiridina inhibitora c-met |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US8987269B2 (hr) |
| EP (5) | EP2719699B1 (hr) |
| JP (5) | JP5337313B2 (hr) |
| KR (3) | KR101905350B1 (hr) |
| CN (3) | CN102906092B (hr) |
| AU (2) | AU2010338712B2 (hr) |
| BR (1) | BR112012016129B1 (hr) |
| CA (1) | CA2785749C (hr) |
| CL (1) | CL2012001752A1 (hr) |
| CO (1) | CO6612235A2 (hr) |
| CU (1) | CU24167B1 (hr) |
| CY (2) | CY1118250T1 (hr) |
| DK (3) | DK3795573T3 (hr) |
| DO (1) | DOP2012000188A (hr) |
| EA (2) | EA025466B1 (hr) |
| EC (1) | ECSP12012011A (hr) |
| ES (4) | ES2546635T3 (hr) |
| GT (1) | GT201200220A (hr) |
| HK (2) | HK1194071A1 (hr) |
| HR (3) | HRP20221090T1 (hr) |
| HU (3) | HUE025504T2 (hr) |
| IL (2) | IL220433B (hr) |
| LT (1) | LT3795573T (hr) |
| ME (1) | ME02211B (hr) |
| MX (1) | MX336996B (hr) |
| MY (1) | MY179933A (hr) |
| NI (1) | NI201200118A (hr) |
| NZ (1) | NZ601128A (hr) |
| PE (3) | PE20130375A1 (hr) |
| PL (3) | PL2719699T3 (hr) |
| PT (3) | PT3795573T (hr) |
| RS (3) | RS61281B1 (hr) |
| SG (1) | SG181781A1 (hr) |
| SI (2) | SI2719699T1 (hr) |
| SM (1) | SMT201500213B (hr) |
| UA (1) | UA107822C2 (hr) |
| WO (1) | WO2011079804A1 (hr) |
| ZA (1) | ZA201205730B (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011079804A1 (en) * | 2009-12-31 | 2011-07-07 | Hutchison Medipharma Limited | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| WO2011145035A1 (en) * | 2010-05-17 | 2011-11-24 | Indian Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
| CN103030654A (zh) * | 2011-10-09 | 2013-04-10 | 济南赛文医药技术有限公司 | 一种小分子c-Met蛋白激酶抑制剂 |
| CN102516046A (zh) * | 2011-11-22 | 2012-06-27 | 太仓市运通化工厂 | 一种2-溴丙醛的合成方法 |
| CA2865719C (en) * | 2012-03-30 | 2020-09-22 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
| CA2776178A1 (en) * | 2012-04-05 | 2013-10-05 | Hydro-Quebec | Ionic compounds |
| KR101745741B1 (ko) | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
| WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| BR112015020787B1 (pt) | 2013-03-06 | 2022-12-06 | Astrazeneca Ab | Compostos 4-(substituído-anilino)-6-o-(substituídopiperizina-carbonil)quinazolínicos, seus sais, composição farmacêutica, uso e combinação |
| CN103265468A (zh) * | 2013-06-17 | 2013-08-28 | 连云港盛和生物科技有限公司 | 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法 |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| EP3053923B1 (en) * | 2013-09-30 | 2018-04-11 | Korea Research Institute of Chemical Technology | Triazolopyrazine derivatives as tyrosin kinase inhibitors |
| SG11201605207PA (en) * | 2013-12-26 | 2016-07-28 | Ignyta Inc | Pyrazolo[1,5-a]pyridine derivatives and methods of their use |
| JP2016048495A (ja) * | 2014-08-28 | 2016-04-07 | 京セラ株式会社 | 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法 |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| CN106928232B (zh) * | 2015-12-31 | 2019-07-09 | 上海医药集团股份有限公司 | 喹啉类化合物及其盐的晶型、制备方法、组合物与应用 |
| GB201616116D0 (en) | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| KR20180092096A (ko) | 2017-02-08 | 2018-08-17 | 에이비온 주식회사 | 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
| EP3589628A4 (en) | 2017-03-01 | 2021-03-31 | Achillion Pharmaceuticals, Inc. | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES |
| CN108570053A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元并六元杂环化合物、制备方法、中间体、组合和应用 |
| KR101924801B1 (ko) | 2017-08-16 | 2018-12-04 | 한국원자력의학원 | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| BR112021004263A2 (pt) | 2018-09-06 | 2021-05-25 | Achillion Pharmaceuticals, Inc. | formas mórficas de danicopano |
| MX2021002794A (es) * | 2018-09-11 | 2021-08-11 | Astrazeneca Ab | Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma. |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| CA3118218A1 (en) * | 2018-10-30 | 2020-05-07 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| EP3893872A4 (en) | 2018-12-14 | 2022-08-10 | Beta Pharma, Inc. | COMPOUNDS SUBSTITUTED BY ORGANOPHOSPHORUS AS C-MET INHIBITORS AND THEIR THERAPEUTIC USES |
| JP2022541825A (ja) * | 2019-07-22 | 2022-09-27 | リペア セラピューティクス インコーポレイテッド | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
| WO2021168320A1 (en) * | 2020-02-20 | 2021-08-26 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| WO2021229605A1 (en) * | 2020-05-14 | 2021-11-18 | Dr. Reddy's Laboratories Limited | Process for preparation of savolitinib and its intermediates |
| JP2023543990A (ja) * | 2020-09-28 | 2023-10-19 | コデクシス， インコーポレイテッド | キラルアミンを合成するための操作された生体触媒および方法 |
| EP4263523A2 (en) * | 2020-12-16 | 2023-10-25 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4275678A1 (en) | 2021-01-08 | 2023-11-15 | Abion Inc. | Method for preparing tablet of pharmaceutical composition comprising triazolopyrazine derivative compound as active ingredient |
| CN113278019A (zh) * | 2021-05-31 | 2021-08-20 | 河南偶联生物科技有限公司 | 一种咪唑并[1,2-a]吡啶类化合物的合成方法 |
| WO2023205722A1 (en) * | 2022-04-20 | 2023-10-26 | Engrail Therapeutics, Inc. | Gabaa receptor modulator salts, particles, and uses thereof |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| CN115611802B (zh) * | 2022-12-02 | 2023-03-14 | 北京迪泰医药科技有限公司 | 一种3-乙酰基-2-氯吡啶的合成方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| US6979505B2 (en) * | 2003-06-09 | 2005-12-27 | Utc Fuel Cells, Llc | Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant |
| BRPI0412003A (pt) * | 2003-07-02 | 2006-08-15 | Sugen Inc | arilmetil triazol e imidazopirazinas como inibidores de c-met |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
| JP2008508303A (ja) | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | ピロロ−ピリジンキナーゼモジュレーター |
| EP1786811A2 (en) | 2004-08-18 | 2007-05-23 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| ES2347172T3 (es) * | 2005-02-16 | 2010-10-26 | Astrazeneca Ab | Compuestos quimicos. |
| AU2006320580B2 (en) | 2005-11-30 | 2011-06-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| MX2008008277A (es) * | 2005-12-21 | 2009-03-04 | Janssen Pharmaceutica Nv | Triazolopiridazinas como moduladores de tirosina cinasa. |
| NL2000613C2 (nl) * | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| EP2032578A2 (en) | 2006-05-30 | 2009-03-11 | Pfizer Products Incorporated | Triazolopyridazine derivatives |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| TW200817410A (en) | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
| EP2066676A1 (en) | 2006-09-18 | 2009-06-10 | Vertex Pharmaceuticals, Inc. | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF |
| KR20090071612A (ko) | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
| PT2081937E (pt) * | 2006-10-23 | 2012-10-15 | Sgx Pharmaceuticals Inc | Moduladores de proteína-cinase de triazolo-piridazina |
| JP5572388B2 (ja) | 2006-11-22 | 2014-08-13 | インサイト・コーポレイション | キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン |
| BRPI0809500A2 (pt) | 2007-04-10 | 2014-09-23 | Sgx Pharmaceuticals Inc | Composto, e, métodos para modular a atividade de uma proteína quinase e para tratar uma doença |
| WO2008138842A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| CA2717034A1 (en) | 2008-02-28 | 2009-09-03 | Pascal Furet | Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| CA2724715A1 (en) | 2008-05-22 | 2009-11-26 | Amgen Inc. | Heterocycles as protein kinase inhibitors |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
| AU2010283806A1 (en) * | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| KR20120089463A (ko) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | 헤테로시클릭 옥심 화합물 |
| WO2011079804A1 (en) * | 2009-12-31 | 2011-07-07 | Hutchison Medipharma Limited | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| WO2011145035A1 (en) | 2010-05-17 | 2011-11-24 | Indian Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
-
2010
- 2010-12-30 WO PCT/CN2010/080499 patent/WO2011079804A1/en active Application Filing
- 2010-12-30 EP EP13198224.1A patent/EP2719699B1/en active Active
- 2010-12-30 SG SG2012044830A patent/SG181781A1/en unknown
- 2010-12-30 DK DK20199091.8T patent/DK3795573T3/da active
- 2010-12-30 PT PT201990918T patent/PT3795573T/pt unknown
- 2010-12-30 HU HUE13198224A patent/HUE025504T2/en unknown
- 2010-12-30 US US13/501,222 patent/US8987269B2/en active Active
- 2010-12-30 CA CA2785749A patent/CA2785749C/en active Active
- 2010-12-30 RS RS20201567A patent/RS61281B1/sr unknown
- 2010-12-30 PL PL13198224T patent/PL2719699T3/pl unknown
- 2010-12-30 MY MYPI2012002974A patent/MY179933A/en unknown
- 2010-12-30 AU AU2010338712A patent/AU2010338712B2/en active Active
- 2010-12-30 MX MX2012007756A patent/MX336996B/es active IP Right Grant
- 2010-12-30 PL PL19151824T patent/PL3511330T3/pl unknown
- 2010-12-30 PL PL20199091.8T patent/PL3795573T3/pl unknown
- 2010-12-30 ES ES13198224.1T patent/ES2546635T3/es active Active
- 2010-12-30 UA UAA201208929A patent/UA107822C2/ru unknown
- 2010-12-30 HU HUE20199091A patent/HUE059696T2/hu unknown
- 2010-12-30 CU CU20120101A patent/CU24167B1/es active IP Right Grant
- 2010-12-30 PE PE2012000903A patent/PE20130375A1/es not_active Application Discontinuation
- 2010-12-30 KR KR1020177022937A patent/KR101905350B1/ko active IP Right Grant
- 2010-12-30 KR KR1020147010967A patent/KR101771299B1/ko active IP Right Grant
- 2010-12-30 ES ES20199091T patent/ES2927146T3/es active Active
- 2010-12-30 RS RS20150584A patent/RS54217B1/en unknown
- 2010-12-30 EP EP15170608.2A patent/EP2966075B1/en active Active
- 2010-12-30 NZ NZ601128A patent/NZ601128A/en unknown
- 2010-12-30 EA EA201200951A patent/EA025466B1/ru not_active IP Right Cessation
- 2010-12-30 SI SI201031021T patent/SI2719699T1/sl unknown
- 2010-12-30 ME MEP-2015-150A patent/ME02211B/me unknown
- 2010-12-30 RS RS20220854A patent/RS63612B1/sr unknown
- 2010-12-30 CN CN201080065014.1A patent/CN102906092B/zh active Active
- 2010-12-30 JP JP2012546344A patent/JP5337313B2/ja active Active
- 2010-12-30 DK DK13198224.1T patent/DK2719699T3/en active
- 2010-12-30 HR HRP20221090TT patent/HRP20221090T1/hr unknown
- 2010-12-30 SI SI201032046T patent/SI3511330T1/sl unknown
- 2010-12-30 HU HUE19151824A patent/HUE052828T2/hu unknown
- 2010-12-30 PT PT191518240T patent/PT3511330T/pt unknown
- 2010-12-30 PT PT131982241T patent/PT2719699E/pt unknown
- 2010-12-30 KR KR1020127019509A patent/KR101434766B1/ko active IP Right Grant
- 2010-12-30 PE PE2020001800A patent/PE20211094A1/es unknown
- 2010-12-30 CN CN201610437304.3A patent/CN106117248B/zh active Active
- 2010-12-30 ES ES19151824T patent/ES2840454T3/es active Active
- 2010-12-30 EA EA201691461A patent/EA030141B1/ru not_active IP Right Cessation
- 2010-12-30 EP EP10840591.1A patent/EP2519524A4/en not_active Withdrawn
- 2010-12-30 EP EP19151824.0A patent/EP3511330B1/en active Active
- 2010-12-30 PE PE2016000292A patent/PE20160588A1/es unknown
- 2010-12-30 BR BR112012016129-6A patent/BR112012016129B1/pt active IP Right Grant
- 2010-12-30 EP EP20199091.8A patent/EP3795573B1/en active Active
- 2010-12-30 LT LTEP20199091.8T patent/LT3795573T/lt unknown
- 2010-12-30 CN CN201610432059.7A patent/CN106432225B/zh active Active
- 2010-12-30 ES ES15170608T patent/ES2726152T3/es active Active
- 2010-12-30 DK DK19151824.0T patent/DK3511330T3/da active
-
2012
- 2012-04-10 US US13/501,224 patent/US8507487B2/en active Active
- 2012-06-14 IL IL220433A patent/IL220433B/en active IP Right Grant
- 2012-06-26 CL CL2012001752A patent/CL2012001752A1/es unknown
- 2012-06-28 GT GT201200220A patent/GT201200220A/es unknown
- 2012-06-29 DO DO2012000188A patent/DOP2012000188A/es unknown
- 2012-06-29 CO CO12109937A patent/CO6612235A2/es not_active Application Discontinuation
- 2012-06-29 NI NI201200118A patent/NI201200118A/es unknown
- 2012-06-29 EC EC2012012011A patent/ECSP12012011A/es unknown
- 2012-07-30 ZA ZA2012/05730A patent/ZA201205730B/en unknown
-
2013
- 2013-06-11 JP JP2013122502A patent/JP2013209418A/ja active Pending
-
2014
- 2014-07-23 HK HK14107500.2A patent/HK1194071A1/xx unknown
-
2015
- 2015-01-21 US US14/601,674 patent/US20150368271A1/en not_active Abandoned
- 2015-06-23 AU AU2015203480A patent/AU2015203480B2/en active Active
- 2015-07-16 IL IL239997A patent/IL239997A/en active IP Right Grant
- 2015-09-08 HR HRP20150952TT patent/HRP20150952T1/hr unknown
- 2015-09-09 SM SM201500213T patent/SMT201500213B/xx unknown
- 2015-09-17 CY CY20151100816T patent/CY1118250T1/el unknown
-
2016
- 2016-04-04 JP JP2016074893A patent/JP6194046B2/ja active Active
- 2016-04-14 HK HK16104273.2A patent/HK1216880A1/zh unknown
- 2016-10-14 US US15/293,722 patent/US9956218B2/en active Active
-
2017
- 2017-08-10 JP JP2017155493A patent/JP6486999B2/ja active Active
-
2018
- 2018-04-04 US US15/945,324 patent/US10512645B2/en active Active
-
2019
- 2019-02-20 JP JP2019028197A patent/JP6647434B2/ja active Active
- 2019-11-08 US US16/678,091 patent/US10946014B2/en active Active
-
2020
- 2020-12-17 HR HRP20202017TT patent/HRP20202017T1/hr unknown
- 2020-12-21 CY CY20201101206T patent/CY1123777T1/el unknown
-
2021
- 2021-02-03 US US17/248,688 patent/US11896592B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| HRP20220258T1 (hr) | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora | |
| MX2016006919A (es) | Nucleotidos para el tratamiento de cancer de higado. | |
| IL212651A (en) | Preparations for the treatment of acute lymphoblastic leukemia in children | |
| HK1124040A1 (en) | Heteroalkyl linked pyrimidine derivatives | |
| HRP20191461T1 (hr) | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja | |
| GEP201606555B (en) | Compounds and compositions for modulating egfr activity | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| UA111717C2 (uk) | Склад для перорального введення і ліпофільні солі метилналтрексону | |
| PT2155188E (pt) | Métodos e composições para o tratamento de cancro recorrente | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| IL213920A0 (en) | 3,3'-spiroindolinone derivatives as anticancer agents | |
| IL229975A0 (en) | Pharmaceutical compounds containing arsenoic acid, its sodium salt and its antecedents for the treatment of organ cancer and its metastases | |
| IL226377A0 (en) | Preparations of isoflavone nanoparticles and methods for their preparation and use | |
| ZA201204328B (en) | Foundry mixes containing sulfate and/or nitrate salts and their uses | |
| MX2009006075A (es) | Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes. | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| MX2009002492A (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados. | |
| MX2013011231A (es) | Nanoparticulas basadas en lipidos. | |
| MX2017011024A (es) | Desacetoxitubulisina h y analogos de esta. | |
| NZ610851A (en) | Compounds and compositions for the treatment of cancer | |
| MX2018000239A (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
| UA118562C2 (uk) | Модулятори рецептора cxcr7 | |
| MX366857B (es) | Composiciones con bajo contenido de sal de sodio y metodos para elaboracion y utilizacion. | |
| IT1398291B1 (it) | Ferro bisglicinato chelato per uso nel trattamento per via orale dell'anemia in pazienti celiaci. |